Background. In haemodialysis patients, deaths due to cardiovascular causes constitute a large proportion of total mortality and sudden cardiac deaths account for ∼22% of all deaths. The aim of this study was to evaluate the incidence of sudden cardiac death and associated risk factors in a cohort of haemodialysis patients. Methods and results. The 3-year cumulative incidence of death in a cohort of 476 patients on chronic haemodialysis treatment was 34.3% (SE 2.3). Sudden death had a 6.9% (SE 1.2) cumulative incidence, with 32 events representing 19.2% of all deaths, while cardiovascular not sudden death and noncardiovascular death accounted for a 3-year cumulative incidence of 7.3% (SE 1.2) and 20.1% (SE 1.9), respectively. According to Cox multivariate analysis, significant risk factors for sudden death were the presence of atrial fibrillation, diabetes mellitus, predialytic hyperkalaemia, haemodialysis mode and C-reactive protein level, which were associated with a 2.9 (CI 95% 1.3-6.4), 3.0 (CI 95% 1.3-7.2), 2.7 (CI 95% 1.3-5.8), 4.5 (CI 95% 1.3-15.5) and 3.3 (CI 95% 1.2-8. frequent during the first 24 h of the first short interdialytic interval and during the last 24 h of the long interval, i.e. immediately before and immediately after the first weekly haemodialysis session (P = 0.02). Conclusions. Our data show that the incidence of sudden death in haemodialysis patients is high and that atrial fibrillation, diabetes, hyperkalaemia, haemodialysis mode and C-reactive protein play an important role in developing fatal arrhythmia. Further studies will be necessary to define which interventions could be helpful in reducing this cause of mortality.
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Introduction
In spite of continuous improvements in dialytic techniques, mortality in patients on renal replacement therapy with haemodialysis remains high and deaths due to cardiovascular causes constitute a large proportion of total mortality. In the USA, the incident dialysis patients from 2000 to 2002 had a cumulative probability of acute myocardial infarction and congestive heart failure at 3 years of ∼20% and 65%, respectively. The cumulative probability of sudden cardiac death in this population was 24% [1] . Death as a consequence of arrhythmic mechanisms, sustained ventricular tachycardia, ventricular fibrillation or cardiac arrest is much more frequent in haemodialysis patients as compared to the general population [2] . Patients on haemodialysis therapy present numerous factors that may predispose to the onset of life-threatening cardiac arrhythmia. Factors characterizing uraemic heart disease (cardiac hypertrophy, fibrosis and myocardial calcifications, electrolytic alterations and acidosis, sympathetic hyperactivity) as well as factors directly related to the haemodialysis session (acute changes in extracellular volume and in plasmatic electrolytic concentrations and intradialytic alterations in sympatho-vagal balance) are involved. Relatively few data are available in the literature concerning the factors that are associated with sudden death in patients on renal replacement therapy and most come from retrospective studies. The presence of diabetes mellitus and cardiovascular diseases has been associated with sudden death [3] . Paoletti et al. indicated that left ventricular hypertrophy, and specifically the worsening of its severity, is the strongest predictive factor of sudden death in uraemic patients [4] . A recent study by Pareck et al. demonstrated an association between sudden death and some inflammation biomarkers in uraemic patients [5] .
Even if it is known that the haemodialysis session per se has a powerful arrhythmogenic potential, intradialytic sudden deaths are only a minority compared to the total incidence, and the frequency of intradialytic cardiac arrest is seven cases in 100 000 haemodialysis sessions [6] . This fact suggests that the majority of the episodes occur at the patient's home, as described by Bleyer in a recent study [3] .
The objectives of our study are to evaluate the incidence of sudden cardiac death in a population of chronic haemodialysis patients, followed prospectively for a period of 3 years, and to evaluate possible risk factors associated with it. A previous paper on the same patient cohort had described mortality and hospitalization without focusing on sudden death [7] .
Subjects and methods
Data collection was performed by analysing record charts and reports of echocardiography and electrocardiographic examinations from 476 patients who were on chronic haemodialysis treatment in five dialysis centres in Lombardia, Italy. No selection was made and all patients who were treated in the participating centres in June of 2003 were enrolled in the study cohort. Clinical and demographic characteristics were collected, and patients were followed up for 3 years from enrolment, with last update in June 2006. The follow-up charts were filled in by the medical staff of each centre, and subsequently the data were registered into a specific database.
All patients underwent three haemodialysis sessions a week: on Monday, Wednesday and Friday or on Tuesday, Thursday and Saturday. Hence, each week the patients performed three haemodialysis sessions, divided by two intervals of 2 days (short interdialytic interval) and one interval of 3 days (long interdialytic interval).
Causes of death were centrally reviewed. Deaths were classified as cardiovascular only if causes of death included documented heart diseases. Sudden death was defined as unexpected natural death occurring within 1 h after the onset of symptoms. Some pre-existing heart disease could already be known, but anyway time and cause of death were not foreseen. All deaths registered as sudden deaths were confirmed in interviews with the patient's physician or family members.
The criteria adopted to code patient characteristics were the following: ischaemic heart disease was indicated in the case of previous myocardial infarction or coronary revascularization procedures, such as angioplasty or coronary bypass graft. Dilated cardiomyopathy was defined in the presence of echocardiography-documented left ventricular dilation (left ventricular end-diastolic diameter >55 mm) and/or left ventricular dysfunction (left ventricular ejection fraction <50%). Valvular heart disease was determined as the presence of echocardiography documentation of moderate or severe mitral or aortic stenosis and/or regurgitation. Patients were identified as hypertensive when blood pressure values >140/90 mmHg were documented before the start of haemodialysis therapy, or when nephrologists reported the onset of blood pressure predialysis values >140/ 90 mmHg after the start of haemodialysis therapy or when antihypertensive drugs were administered. The presence or absence of atrial fibrillation in one of its forms (paroxysmal, persistent and permanent) was considered. Atrial fibrillation had to be documented by means of electrocardiographic registration. Atrial fibrillation was found in 127 patients (26.7%). The paroxysmal form was present in 16 (3.4%), the persistent form in 43 (9.0%), while atrial fibrillation was permanent in 68 patients (14.3%) of 476 cohort patients.
Collected echocardiography data were left ventricular ejection fraction (left ventricular ejection fraction, %) and the presence of left ventricular hypertrophy, which was defined as left ventricular mass normalized for body surface area >125 g/m 2 according to the Penn-cube formula, or when its presence was described in the report. Diagnosis of hyperkalaemia was made based on at least three predialysis blood samples with serum potassium concentrations of 6.0 mmol/l or greater, in the last 6 months before the recruitment [8] . The levels of haemoglobin and Creactive protein that were considered for analysis were obtained from the mean of values recorded during the last month before recruitment. Reduced haemodynamic tolerance to the dialysis treatment was defined as at least one episode of hypotension in >20% of the dialysis sessions in the 3 months before the start of the study. Intradialytic hypotension was defined as a reduction in systolic blood pressure of 30 mmHg, or more, associated with hypotension symptoms requiring an intervention (such as reducing ultrafiltration rate, administering saline infusion or ending the dialysis session early) or in the case of patients with predialysis systolic arterial pressure <100 mmHg and a reduction of at least 10% of the predialysis values, accompanied by symptoms.
In haemodialysis patients, the presence of classical signs and symptoms of heart failure (dyspnoea and peripheral oedema) may merely be the consequence of an inadequate application of the haemodialysis therapy at that particular moment. Therefore, we preferred to use a more objective criterion based on echocardiography parameters (ventricular diameter and reduced ejection fraction) and on the presence of episodes of acute cardiac failure (acute pulmonary oedema) instead of the usual heart failure definition.
Statistical analysis
The crude cumulative incidence of deaths was estimated accounting for competing risks of sudden, cardiovascular not sudden and noncardiovascular deaths. Observation time was censored at 3 years if the patient survived at the last follow-up, while it was censored before 3 years if a renal transplant had occurred (n = 46) or if the patients had been transferred to another hospital (n = 12) during the follow-up.
The Cox regression model on cause-specific hazard of sudden death was used both to analyse the impact of each candidate risk factor (univariate analysis) and to identify those factors that independently affected the hazard of sudden death (one-step multivariate analysis). By definition of cause-specific hazard, events considered were only sudden deaths, and patients at risk were those alive and under observation at the event time. The assumption of proportional hazards was assessed by means of graphical checks on the log cumulative hazard for each covariate and, since age at recruitment did not satisfy the assumption, the model was stratified by age at recruitment (categorized as in Table 1 ). Variables included as regressors in the model were duration of haemodialysis, presence of atrial fibrillation, ischaemic heart disease, dilated cardiomyopathy and/or acute pulmonary oedema, valvular heart disease, hypertension, diabetes mellitus, left ventricular hypertrophy, left ventricular ejection fraction, QRS duration, hyperkalaemia, haemodialysis mode and C-reactive protein level (a missing data category was included when needed). Results of the Cox model are expressed in terms of estimated hazard ratios (HR) and 95% confidence intervals (CI 95% ).
The Pearson chi-squared test was used to assess whether the time pattern of sudden deaths was associated with the time schedule of dialysis. Observed data were grouped according to whether they occurred or not in the high-risk intervals (death in the first short interval, within 24 h from dialysis, and in the long interval, after 48 h from dialysis) and were compared with the number of deaths expected under uniform distribution. All computations were carried out using SAS, version 9.1 (SAS Institute, Cary, NC, USA).
Results
The population's clinical and demographic characteristics and the incidence of cardiovascular (sudden and not sudden) and noncardiovascular death are described in Table 1 .
With 167 observed deaths, the 3-year cumulative incidence of death in the cohort of 476 haemodialysis patients was 34.3% (SE 2.3). This resulted from 20.1% (SE 1.9) 3-year cumulative incidence due to noncardiovascular causes (100 deaths), 7.3% (SE 1.2) and 6.9% (SE 1.2) due to cardiovascular causes not sudden (35 deaths) and sudden (32 deaths), respectively ( Figure 1 ).
Higher risk of sudden death, as assessed by univariate analysis, was associated with the following factors: older age (P = 0.02), presence of atrial fibrillation (P < 0.001), ischaemic heart disease (P = 0.02), dilated cardiomyopathy (P < 0.001), diabetes mellitus (P = 0.007), left ventricular hypertrophy (P = 0.03), longer QRS duration (P = 0.007), predialytic hyperkalaemia (P = 0.04), bicarbonate dialysis (P = 0.008) and high level of C-reactive protein (P = 0.002). Atrial fibrillation (P = 0.03), ischaemic heart disease (P < 0.001) and valvular disease (P < 0.001) were correlated with not sudden cardiovascular death, while age (P < 0.001), duration of haemodialysis (P = 0.003), atrial fibrillation (P = 0.001), ischaemic heart disease (P = 0.001), dilated cardiomyopathy (P = 0.02) and dialysis mode (P = 0.03) were shown to be factors associated with noncardiovascular mortality. Treatments with beta-blockers and angiotensin-converting enzyme inhibitors were not shown to be protective against any cause-specific mortality and have not been considered in the multivariate analyses.
The cause-specific hazard of sudden death was analysed by means of a multivariate Cox model as shown in Table 2 . The presence of atrial fibrillation, diabetes mellitus, predialytic hyperkalaemia, bicarbonate dialysis and C-reactive protein level >1.9 mg/dl were statistically significant, with a 2.9 (CI 95% 1.3-6.4), 3.0 (CI 95% 1.3-7.2), 2.7 (CI 95% 1.3-5.9), 4.5 (CI 95% 1.3-15.5) and 3.3 (CI 95% 1.2-8.8)-fold increase in the risk of sudden death, respectively. The other factors considered in the multivariate analysis were not significantly associated with outcome.
When the same type of model was applied to the causespecific hazard of not sudden cardiovascular death, the presence of ischaemic heart disease (HR = 2.9, CI 95% 1.4-5.8, P = 0.004) and valvular disease (HR = 5.3, CI 95% 2.1-13.5, P < 0.001) was found to be significantly related to the outcome. The long duration of haemodialysis (HR = 2.1, CI 95% 1.3-3.3, P = 0.002), presence of valvular heart disease (HR = 2.5, CI 95% 1.1-5.6, P = 0.024) and high levels of C-reactive protein (HR = 3.7, CI 95% 1.9-7.1, P < 0.001) were the factors significantly related to the hazard of noncardiovascular death, after stratifying by age at enrolment.
Timing of sudden death was analysed with respect to timing of dialytic sessions during the week. In the absence of any time pattern, the 32 sudden deaths would be uniformly distributed in week days (4.57 per day). It was instead observed that sudden deaths were significantly more frequent than expected during the first 24 h of the first short interdialytic interval (eight deaths) and during the last 24 h of the long interval (seven deaths), (P = 0.02, Figure 2 ).
Discussion
In the present study, we focused our attention on sudden death in a non-selected cohort of 476 haemodialysis patients followed up prospectively for 3 years.
The main results of our study are the following:
-the 3-year cumulative incidence of sudden death in our population was 6.9%, accounting for ∼20% of the total number of deaths; -sudden death was highly and independently associated with the presence of atrial fibrillation, diabetes mellitus and predialytic hyperkalaemia; -the bicarbonate haemodialysis seemed to be significantly related to a higher incidence of sudden death compared to the other dialysis modes; -high level of C-reactive protein, an inflammation marker, showed to be slightly but significantly associated with the incidence of sudden death and -sudden deaths tended to cluster during the first hours of the first short interdialytic interval and during the last hours of the long interval. The incidence and the percentage of sudden death on total mortality found in our cohort are high compared to the general population and similar to those reported in other prospective studies performed in uraemic patients [4, 5, 9] .
According to the definition used by us (sudden and unexpected death, not traumatic, taking place within 1 h from the onset of symptoms), sudden death must be considered essentially caused by cardiac arrhythmia, even if, as we did not perform autopsy in all the deceased patients, it cannot be excluded that some deaths may have had non-arrhythmic causes (myocardial infarction, pulmonary embolism, cerebral infarction and ruptured aneurysm).
In our population atrial fibrillation and diabetes mellitus are the clinical factors that are strongly associated with sudden death. Diabetes is often related to the presence of cardiac disease, like ischaemic heart disease, and consequently it is reasonable to presume that this condition increases the risk of sudden death. The presence of atrial fibrillation represents a marker of severity of all associated heart diseases and it is correlated with increased mortality both in cohorts of patients with heart failure or ischaemic heart disease [10, 11] , in the general population and in patients with lone atrial fibrillation [10, 12] . In addition atrial fibrillation may be a triggering factor of fatal arrhythmia in the presence of a predisposing substrate, such as the heart of patients on renal replacement therapy.
There is evidence showing that left ventricular ejection fraction is the best predictor of total and sudden death in patients with heart failure, dilated cardiomyopathy and previous myocardial infarction, but without end-stage renal disease [13] [14] [15] . In our population, a reduced ejection fraction is not related to cardiovascular and sudden mortality. It must be highlighted that the proportions of subjects with systolic dysfunction and/or ischaemic heart disease were both relatively low in our patients; nevertheless, the mortality due to sudden death was high. Therefore, it may be hypothesized that in the studied patients other factors than those involved in patients with heart failure or ischaemic heart disease play a role in determining sudden death. Among these factors, electrolytic alterations occurring during the haemodialysis session and during the interdialytic intervals may be important. Our study shows that the presence of predialytic hyperkalaemia is an independent predictor of sudden death and, according to Bleyer's data [3] , that two frequency peaks of sudden death are located at the beginning of the first short interdialytic interval and at the end of the long one. The last phase of the long interdialytic interval is characterized by an increase in kalaemia that may lead to conduction disturbances, bradyarrhythmia and even asystole and electromechanical dissociation. Moreover, during the first dialysis session of the week, important and sudden transmembrane ionic movements may occur and induce changes in the duration of action potential and QT interval [16] and, consequently, tachyarrhythmia. This could be particularly true for those patients with the highest serum potassium values, for whom low potassium concentration in the dialysis bath is frequently used. It has been demonstrated that daily haemodialysis is associated with an improvement of some indices related to morbidity and mortality [17] and to a decrease in total mortality itself [18] . The finding of two frequency peaks of sudden death, immediately before and after the first weekly haemodialysis session, suggests that daily haemodialysis, or at least the abolition of the long interdialytic interval during the weekend, could be helpful in reducing this kind of mortality.
In patients with heart failure and after myocardial infarction, when markers of increased risk of sudden death are present (especially reduced ejection fraction), it would be indicated to implant a cardioverter-defibrillator. Several trials show that this intervention may reduce total mortality by 20-50% [19] [20] [21] , but in these studies subjects with end-stage renal disease were not included.
In a large retrospective study, Herzog reported that an implantable cardioverter-defibrillator was associated with improved survival of haemodialysis patients who survived cardiac arrest [22] . However, literature data show that the survival time in cardioverter-defibrillator recipients is shorter in subjects with end-stage renal disease than in patients without it [23] [24] [25] , and adverse effects related to the defibrillator implantation have been reported at a higher frequency in patients on renal replacement therapy compared to other populations [26] . We do not think that in all patients with end-stage renal disease the presence of risk factors for sudden death found in our series (i.e. atrial fibrillation and diabetes) have to be taken as mandatory criteria for implantable defibrillator indication, especially in view of their quality of life and of the limited life expectancy. On the other hand, even in the presence of end-stage renal disease, an implantable cardioverter-defibrillator could be helpful in those subjects with a reduced ejection fraction and heart failure or after myocardial infarction, the population in which it is a consolidated tool against sudden death. Prospective trials to assess the benefits of prophylactic cardiac device therapy in end-stage renal disease are required to investigate the role of this kind of therapy on survival.
In our population, bicarbonate haemodialysis was associated with a higher incidence of sudden death compared to the other dialysis modes. Even if this finding could have clinical relevance, it has the value of a simple observation, because the patients were not randomized according the dialysis mode. A prospective trial on this topic may be desirable to evaluate the importance of this observation.
Our results show that high levels of C-reactive protein are an independent predictor of sudden death. This observation agrees with information in literature, both concerning heart disease patients [27, 28] and patients on haemodialysis therapy [5] . Our data confirm the existence, also in uraemic patients, of an association between chronic inflammation and cardiovascular events, including major arrhythmias.
Limitations of the study
Some parameters that could be important for the understanding of the causal mechanisms that contributed to sudden death were not evaluated (e.g. patients' weight at the start of the study) or were not available in all patients (e.g. ejection fraction, QRS duration, interdialytic weight gain, intradialytic hypotension, levels of C-reactive protein and haemoglobin).
In conclusion, our study confirms the presence of a high incidence of sudden death in haemodialysis patients and suggests that in this population the associated factors may be partially different from those found in the cardiac disease patients population. Daily haemodialysis, avoiding low potassium in dialysis bath, prophylactic cardioverterdefibrillator implantation and nephrologists' particular attention to the clinical management of subjects who present an elevated risk (i.e. patients with atrial fibrillation and/or diabetes) could be helpful in reducing this kind of mortality. Further studies are required to investigate the role of the different interventions aimed to prevent sudden death in the end-stage renal disease population. Correspondence and offprint requests to: Liviu Segall; E-mail: l_segall@yahoo.com Abstract Background. Protein-energy wasting is a common complication and an important predictive factor for mortality in chronic dialysis patients. Therefore, nutritional status needs to be regularly assessed in these patients, by using several methods, and, if malnutrition is present, its possible causes should be thoroughly searched for and properly treated. Material and Methods. In 149 prevalent haemodialysis patients (82 men, mean age 53.9 ± 13.7 years), we evaluated the nutritional status by anthropometrics [post-dialysis height (H), body weight (BW), body mass index (BMI), mid-arm circumference (MAC), tricipital skin-fold thickness (TST), mid-arm muscle circumference (MAMC), corrected mid-arm muscle area (cMAMA) and three-category subjective global assessment score (SGA)], biochemical tests [protein equivalent of nitrogen appearance (nPNA), and pre-dialysis serum albumin, creatinine, total cholesterol, bicarbonate and haemoglobin (Hb) levels] and bioelectrical impedance analysis (BIA) to estimate body composition [percent body fat (%BF), fat-free mass (%FFM), body cell mass (%BCM), extracellular mass (%ECM) and the phase angle (PhA)]. Results. Age was found to be positively correlated with BMI (P = 0.001), and inversely correlated with %BCM (P = 0.013). Patients with A-category SGA were significantly younger (50.1 versus 63.7 years) than those with B-category SGA. Patients with diabetes had lower %BCM (32.9 versus 35.9%; P = 0.035) and PhA (5.5 versus 6.9
• ; P = 0.0007) than those without diabetes. The presence of heart failure was associated with significantly reduced nPNA (1.17 versus 1.34 g/kg day; P = 0.014), MAMC (22.0 versus 23.6 cm 2 ; P = 0.041), %BCM (33.0 versus 36.1; P = 0.021), PhA (5.8 versus 7.0
• ; P = 0.031), serum albumin (39.7 versus 42.4 g/l; P = 0.013) and serum creatinine (8.1 versus 9.4 mg/dl; P = 0.010), and with a higher percent of B-category SGA (47.8% versus 22.6%; P = 0.019). Eleven deaths (7.4%) occurred during the followup period. Among general factors, age ≥ 55, the presence of diabetes, and dialysis vintage <2 years were associated with significantly reduced survival. Among nutritional factors, B-category SGA, nPNA <1.2 g/kg day, %BF <15% and PhA <6
• significantly predicted mortality in both KaplanMeier and Cox analyses. The most important risk factor appeared to be nPNA; for every 0.1 g/kg day increase in nPNA, death risk decreased by 15%. Conclusions. In our haemodialysis patients, advancing age, diabetes and heart failure were associated with worse nutritional status, as estimated by anthropometry, biochemical markers and BIA. Age ≥55 years, the presence of diabetes, nPNA <1.2 g/kg day, lower SGA score, %BF <15% and PhA <6
• were associated with significantly increased death risk.
